Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depression

American Journal of Geriatric Psychiatry

Volumn 10, Issue 6, 2002, Pages 715-723

  Smith, Gwenn S ^a,b   Kramer, Elisse ^a   Hermann, Carol R ^b   Goldberg, Sara ^b   Ma, Yilong ^b   Dhawan, Vijay ^b   Barnes, Anna ^b   Chaly, Thomas ^b   Belakhleff, Abdel ^b   Laghrissi Thode, Fouzia ^c   Greenwald, Blaine ^a   Eidelberg, David ^b   Pollock, Bruce G ^d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b North Shore Long Island Jewish Health System   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; GLUCOSE; PLACEBO; SEROTONIN; ANTIDEPRESSANT AGENT;

ACUTE DRUG ADMINISTRATION; ADULT; AGED; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE MARKER; DRUG EFFECT; DRUG SAFETY; FEMALE; GLUCOSE METABOLISM; HEMISPHERIC DOMINANCE; HUMAN; MALE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SEROTONIN METABOLISM; VISUAL ANALOG SCALE; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; PAIN ASSESSMENT; SCINTISCANNING; TIME;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; CITALOPRAM; DEPRESSIVE DISORDER; FEMALE; GLUCOSE; HUMANS; MALE; PAIN MEASUREMENT; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036845052     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200211000-00010     Document Type: Article

References (40)

1. Dew MA, Reynolds CF III, Houck PR, et al: Temporal profiles of the course of depression during treatment: Predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 1997; 54:1016-1024
2. Little JT, Reynolds CF III, Dew MA, et al: How common is resistance to treatment in recurrent, nonpsychotic geriatric depression? Am J Psychiatry 1998; 155:1035-1038
3. Maes M, Meltzer H: The serotonin hypothesis of major depression, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom F, Kupfer D. New York, Raven, 1995, pp 933-944
4. Owens MJ, Nemeroff CB: The serotonin transporter and depression. Depress Anxiety 1998, 8(suppl1):5-12
5. Mann JJ: Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999; 21(suppl2):99S-105S
6. Meltzer C, Smith G, DeKosky S, et al: Serotonin in aging, late-life depression, and Alzheimer's disease: The emerging role of functional imaging. Neuropsychopharmacology 1998; 18:407-430
7. Mann JJ, McBride PA, Malone KM, et al: Blunted serotonergic responsivity in depressed inpatients. Neuropsychopharmacology 1995; 13:53-64
8. Mann JJ, Malone KM, Diehl DJ, et al: Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatry 1996; 153:174-182
9. 2O PET response to intravenous d-fenfluramine. Am J Psychiatry 1998; 155:1241-1246
10. Malone KM, Thase ME, Mieczkowski T, et al: Fenfluramine challenge test as a predictor of outcome in major depression. Psychopharmacol Bull 1993; 29:155-161
11. Kapitany T, Schindl M, Schindler S, et al: The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 1999; 88:75-88
12. 2 receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 2001; 50:313-322
13. Anand A, Verhoeff P, Seneca N, et al: Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000; 157:1108-1114
14. Newhouse PA, Sunderland T, Tariot PN, et al: The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry 1988; 45:906-912
15. Kapur S, Mann JJ: Role of the dopaminergic system in depression. Biol Psychiatry 1992; 32:1-17
16. Brown AS, Gershon S: Dopamine and depression. J Neural Trans 1993; General Section 91(2-3):75-109
17. Janowsky DS, Overstreet DH: The role of acetylcholine mechanisms in mood disorders, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York, Raven, 1995, pp 945-956
18. Alexopoulos G, Katz IR, Reynolds CF III, et al: Pharmacotherapy of Depressive Disorders in Older Patients. Postgrad Med Special Report 2001, 1-88
19. 18F]-setoperone PET. Psychopharmacology 1999; 144:279-281
20. Smith G, Kirschner MA, Soriso D, et al: Evaluation of citalopram as a pharmacologic intervention of the serotonin system (abstract). Biol Psychiatry 200; 47(suppl1):99
21. Wu J, Buchsbaum MS, Gillin JC, et al: Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry 1999; 156:1149-1158
22. Smith G, Reynolds CF III, Houck P, et al: The glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry 2002; 10:561-567
23. Mayberg HS, Brannan SK, Tekell JL, et al: Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response. Biol Psychiatry 2000; 48:830-843
24. Smith G, Ma Y, Dhawan V, et al: Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. Synapse 2002; 45:105-112
25. Mulsant B, Houck P, Gildengers A, et al: What is the optimal duration of an acute antidepressant trial when treating geriatric depression? (abstract) Am J Geriatr Psychiatry 2002; 10(suppl1):75
26. Sackeim H: How long should antidepressant trials be in geriatric depression? (abstract) Am J Geriatr Psychiatry 2002; 10(suppl1):42
27. First M, Spitzer R, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCID-I/P). New York, New York Psychiatric Institute, 1995
28. National Institute of Mental Health: Clinical Global Impressions, in Manual for the ECDEU Assessment Battery, 2nd Edition. Edited by Guy W, Bonato RR. Rockville, MD, National Institute of Mental Health, 1976, p 12
29. Guy W: ECDEU: An Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare Publication (ADM) 1976, 76:336
30. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
31. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
32. Beck AT, Steer RA, Ball R, et al: Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996; 67:588-597
33. Yesavage JA: Geriatric Depression Scale. Psychopharmacol Bull 1988; 24:709-711
34. Dhawan V, Kazumata K, Robeson W, et al: Quantitative brain PET: Comparison of 2-D and 3-D acquisition on the GE Advance Scanner. Clinical Positron Imaging 1998; 1:135-144
35. Takikawa S, Dhawan V, Spetsieris P, et al: Noninvasive quantitative fluorodeoxylucose PET studies with an estimated input function derived from a population-based arterial blood curve. Radiology 1993; 188:131-136
36. , Friston KJ, Holmes AP, Worsley, KJ, et al: Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapp 1995; 2:189-210
37. Smith G, Reynolds C, Pollock, B, et al: Acceleration of the cerebral glucose metabolic response to antidepressant treatment by total sleep deprivation in geriatric depression. Am J Psychiatry 1999; 156:683-689
38. Buchsbaum MS, Wu J, Siegel BV, et al: Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 1997; 41:15-22
39. Nobler MS, Roose SP, Prohovnik I, et al: Regional cerebral blood flow in mood disorders, V: Effects of antidepressant medication in late-life depression. Am J Geriatr Psychiatry 2000; 8:289-296
40. Little J, Smith G, Meltzer C, et al: Cerebral metabolic changes with paroxetine treatment in geriatric depression. Am J Geriatr Psychiatry 2002; 10(suppl1):73